15 reports of this reaction
1.9% of all ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE reports
#11 most reported adverse reaction
INSOMNIA is the #11 most commonly reported adverse reaction for ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE, manufactured by Method Pharmaceuticals. There are 15 FDA adverse event reports linking ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE to INSOMNIA. This represents approximately 1.9% of all 778 adverse event reports for this drug.
Patients taking ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE who experience insomnia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INSOMNIA is a less commonly reported adverse event for ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE, but still significant enough to appear in the safety profile.
In addition to insomnia, the following adverse reactions have been reported for ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE:
The following drugs have also been linked to insomnia in FDA adverse event reports:
INSOMNIA has been reported as an adverse event in 15 FDA reports for ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
INSOMNIA accounts for approximately 1.9% of all adverse event reports for ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE, making it a notable side effect.
If you experience insomnia while taking ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.